FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to experimental cardiology, and can be used to study pathogenetic mechanisms of development, progression of diabetic phenotype of chronic heart failure. Twelve-month male and female rats are fed on a high-calorie diet that includes the main fodder and additionally 50 g/kg of lard and 10 g/kg of butter for 42 days. Diet involves a single intravenous injection of 2.5% nicotinamide in dose of 250 mg/kg. On 21st day of the experiment, streptozotocin is administered in dose of 40 mg/kg. From 28th to 42nd day of the experiment, the daily introduction of 1% mesatone in dose of 0.5 ml/kg is started intramuscularly with underlying physical activity for 15 minutes.
EFFECT: method enables to study new signalling pathways and molecular targets of pathogenesis of chronic heart failure associated with type 2 diabetes mellitus at the preclinical stage, and approbation of new agents and methods of its prevention and treatment.
1 cl, 4 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CORRECTING COMPLEX OF METABOLIC AND HORMONAL PARAMETERS IN TYPE 2 DIABETES MELLITUS USING INTRANASALLY ADMINISTERED INSULIN | 2023 |
|
RU2827354C1 |
| METHOD OF EXPERIMENTAL MODELING OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH MENOPAUSE IN FEMALE WISTAR RATS | 2022 |
|
RU2808010C1 |
| METHOD FOR SIMULATING ATHEROSCLEROSIS AGAINST BACKGROUND OF DIABETES MELLITUS IN EXPERIMENT | 2020 |
|
RU2748506C1 |
| PHARMACEUTICAL COMPOSITION, MEDICATION FOR PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND DIABETIC NEPHROPATHY AND METHOD OF OBTAINING THEREOF | 2011 |
|
RU2519744C2 |
| METHOD FOR COMBINED USE OF INTRANASALLY ADMINISTERED INSULIN AND ORALLY ADMINISTERED METFORMIN FOR RECOVERY OF METABOLIC AND HORMONAL PARAMETERS IN TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME | 2023 |
|
RU2824275C1 |
| AGENT POSSESSING HYPOLIPIDEMIC ACTIVITY | 2020 |
|
RU2732503C1 |
| METHOD FOR SIMULATING OSTEOARTHROSIS | 2015 |
|
RU2587039C1 |
| METHOD FOR THE COMBINED TREATMENT OF CHRONIC HEART FAILURE AGAINST THE BACKGROUND OF TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2785744C1 |
| USE OF RHODANINE DERIVATIVE 3-(2-PHENYLETHYL)-2-THIOXO-1,3 THIAZOLIDIN-4-ONE FOR CORRECTION OF METABOLIC DISORDERS | 2019 |
|
RU2768171C2 |
| USE OF SODIUM SALT OF DIETHYL ESTER OF 4-OXO-1,4-DIHYDROPYRAZOLO[5,1-C]-1,2,4-TRIAZINE-3,8-DICARBOXYLIC ACID, MONOHYDRATE AS DRUG FOR TREATMENT AND PREVENTION OF LATE COMPLICATIONS OF DIABETES MELLITUS | 2019 |
|
RU2765117C2 |
